Related Experiment Video
Updated: Apr 16, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
[Ketamine--a new treatment option for therapy-resistant depression]
Abstract:
The anaesthetic ketamine has been demonstrated to have an antidepressive effect in several randomised controlled studies. Patients with a severe therapy-resistant depression showed response rates of up to 70 % after one single ketamine infusion. In contrast to all other antidepressant treatment options, this effect was already apparent at 24 hours post infusion. However, the antidepressant effect is limited and after two weeks the relapse rate is around 70 %. This review gives a summary of the clinical value of ketamine in the treatment of depression focussing on clinical trials and the therapeutic mechanism of action.
More Related Videos
09:30Treating Clinical Depression with Repetitive Deep Transcranial Magnetic Stimulation Using the Brainsway H1-coil
Published on: October 4, 2016
12:19Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
Related Concept Videos
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Therapy
Antianxiety Medications